The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717 ...

Disclosure: BH King is a consultant and has received research support from Neuropharm, Seaside Therapeutics, Biomarin, Autism Speaks, and the National Institutes of Health. Z Brkanac and WH ...